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Improved molecular understanding of the pathogenesis of type 2 diabetes is essential if current therapeutic and
preventative options are to be extended. To identify diabetes-susceptibility genes, we have completed a primary
(418-marker, 9-cM) autosomal-genome scan of 743 sib pairs (573 pedigrees) with type 2 diabetes who are from
the Diabetes UK Warren 2 repository. Nonparametric linkage analysis of the entire data set identified seven regions
showing evidence for linkage, with allele-sharing LOD scores 1.18 ( ). The strongest evidence was seenP  .01
on chromosomes 8p21-22 (near D8S258 [LOD score 2.55]) and 10q23.3 (near D10S1765 [LOD score 1.99]), both
coinciding with regions identified in previous scans in European subjects. This was also true of two lesser regions
identified, on chromosomes 5q13 (D5S647 [LOD score 1.22] and 5q32 (D5S436 [LOD score 1.22]). Loci on 7p15.3
(LOD score 1.31) and 8q24.2 (LOD score 1.41) are novel. The final region showing evidence for linkage, on
chromosome 1q24-25 (near D1S218 [LOD score 1.50]), colocalizes with evidence for linkage to diabetes found in
Utah, French, and Pima families and in the GK rat. After dense-map genotyping (mean marker spacing 4.4 cM),
evidence for linkage to this region increased to a LOD score of 1.98. Conditional analyses revealed nominally
significant interactions between this locus and the regions on chromosomes 10q23.3 ( ) and 5q32 (Pp .01 Pp
). These data, derived from one of the largest genome scans undertaken in this condition, confirm that individual.02
susceptibility-gene effects for type 2 diabetes are likely to be modest in size. Taken with genome scans in other
populations, they provide both replication of previous evidence indicating the presence of a diabetes-susceptibility
locus on chromosome 1q24-25 and support for the existence of additional loci on chromosomes 5, 8, and 10.
These data should accelerate positional cloning efforts in these regions of interest.
Introduction
Type 2 diabetes (T2D [MIM 125853]) is a global disease
of rapidly increasing prevalence, for which current pre-
Received May 21, 2001; accepted for publication July 9, 2001;
electronically published August 1, 2001.
Address for correspondence and reprints: Prof. Mark McCarthy,
Professor of Genomic Medicine, Imperial College Genetics and Geno-
mics Research Institute, Imperial College (Hammersmith Campus),
London W12 0NN. E-mail: m.mccarthy@ic.ac.uk
 2001 by The American Society of Human Genetics. All rights reserved.
0002-9297/2001/6903-0009$02.00
ventative and therapeutic strategies remain suboptimal.
It is estimated that ∼160 million people worldwide have
T2D, a figure expected to rise by 40%by 2010 (McCarty
and Zimmet 1994). Furthermore, T2D is one component
of a broader constellation of phenotypes (including hy-
perlipidemia, central obesity, and hypertension—the
“metabolic syndrome”) that contribute in a major way
to the burden of cardiovascular morbidity and mortality
and that therefore represent dominant causes of disease
worldwide (Reaven 1988). Further advances in treating
or preventing these disorders are predicated on an im-
proved molecular description of their pathogenesis. To
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this end, recognition that individual susceptibility to
T2D has a substantial genetic component provides a
coherent framework for efforts to elucidate the funda-
mental disease processes.
The relative recurrence risk of T2D in first-degree
relatives of affected subjects is 3.5 in European popu-
lations (Ko¨bberling and Tillil 1982; Rich 1990). Can-
didate-gene studies have identified several loci with
modest effects on T2D susceptibility (Kadowaki et al.
1994; Hani et al. 1998, 1999; Altshuler et al. 2000;
Huxtable et al. 2000). In addition, the past 5 years have
seen global (i.e., genomewide) scans for linkage that
have been conducted in a wide range of populations,
including African Americans (Ehm et al. 2000), Ash-
kenazim (Permutt et al. 2001), Finns (Mahtani et al.
1996; Ghosh et al. 2000; Watanabe et al. 2000), French
(Vionnet et al. 2000), Mexican Americans (Hanis et al.
1996; Duggirala et al. 1999; Ehm et al. 2000), Native
Americans (Hanson et al. 1998) and individuals in the
United States who are of European descent (Elbein et
al. 1999; Ehm et al. 2000). Although several regions
showing evidence for linkage have emerged from these
studies, and although at least one susceptibility gene
(i.e., CAPN10, for calpain 10 [MIM 605286]; Hori-
kawa et al. 2000) has subsequently been identified by
linkage-disequilibrium mapping, these analyses have re-
inforced the concept of T2D as an etiologically complex,
heterogeneous, and multifactorial condition, with in-
dividual susceptibility determined by the integrated ef-
fect of variation at multiple genetic loci and predispos-
ing environmental exposures.
The reduction in power that is associated with sus-
ceptibility-gene–discovery efforts in the presence of
complex etiology may be ameliorated by the analysis of
large samples, by careful attention to population selec-
tion so as to minimize the possible effects of ethnic and
clinical heterogeneity, and, arguably, by use of popu-
lation isolates (Lernmark and Ott 1998; Ott 1999, p.
321). In certain circumstances, statistically controlled
exploratory methods, such as stratification based on
quantitative phenotypes (Ghosh et al. 1999) and con-
ditional analyses (Cox et al. 1999), may yield increases
in power (Leal and Ott 2000). Support for a putative
susceptibility locus is enhanced considerably by statis-
tically significant replication in additional populations:
indeed, such replication is widely considered a vital
component in the assessment of complex-trait linkage
effects (Lander and Kruglyak 1995).
The Warren 2 Consortium was established by Dia-
betes UK (formerly the British Diabetic Association) to
contribute to global efforts to identify T2D-suscepti-
bility genes. The objectives have been to assemble a
number of substantial patient and family cohorts of
U.K. individuals of European descent and to exploit
these to advance understanding of the genetic basis of
T2D in northern-European populations. Here, we re-
port the results of the autosomal genomewide scan for
linkage, conducted in a total of 573 U.K. families that
were multiplex for T2D, together with the fine-scale
mapping data obtained from one of the chromosomal
regions implicated by the primary analysis.
Subjects and Methods
Subjects
The Warren 2 Sib Pair Repository (see the Warren 2
Project Information [Wellcome Trust Centre for Human
Genetics, Oxford] web site) currently comprises 843 sib-
ship pedigrees ascertained, during 1995–98, through six
U.K. research centers (two in London and one each in
Exeter, Oxford, Cambridge/Norwich, andNewcastle), ac-
cording to a unified ascertainment protocol. All ascer-
tained families include, at minimum, a sib pair with T2D,
together with parents and additional siblings when avail-
able. Validation of the diagnosis of diabetes in the index
sib pair was based on either current prescribed treatment
with sulfonyl ureas, biguanides, and/or insulin or, in the
case of individuals treated with diet alone, historical or
contemporary laboratory evidence of hyperglycemia (as
defined by World Health Organization [1985] guidelines
in place at the time of recruitment). Age at diagnosis
(AAD), of both members of the index sib pair, was ini-
tially restricted to the age range 35–75 years and subse-
quently was narrowed to 35–70 years, with 97.6% fam-
ilies meeting the latter criterion. Other forms of diabetes
(e.g., maturity-onset diabetes of the young, mitochondrial
diabetes, and type 1 diabetes) were excluded by standard
clinical criteria based personal and family history, includ-
ing an absence of first-degree relatives with type 1 diabetes
and an interval of 1 year between diagnosis and insti-
tution of regular insulin therapy. In addition (see the fol-
lowing paragraph), evidence for autoimmunity to islet
antigens was sought by measurement of titers of anti-
bodies to glutamic acid decarboxylase (anti-GAD). All
sibships were of European descent, with all four grand-
parents having exclusively British and/or Irish origin, both
by self-reported ethnicity and by place of birth. Finally,
pedigrees either reporting bilineal inheritance (both par-
ents diabetic) or having a high proportion of affected
individuals within large sibships were excluded from
collection.
These 843 pedigrees included a total of 2,147 ascer-
tained individuals, 2,112 siblings (of whom 1,820 were
diabetic), and 35 parents (15 of whom were diabetic).
The numbers of affected siblings in the sibships ranged
from 2 (in 729 pedigrees) to 5 (in 5 pedigrees). All avail-
able pedigree members were assessed for standard an-
thropometric measures (weight, height, and waist and
hip circumferences). Blood samples were taken for DNA
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extraction and the establishment of transformed cell
lines (undertaken at the European Collection of Cell Cul-
tures, Centre for AppliedMicrobiology&Research, Sal-
isbury, England). Serum was reserved from all diabetic
sibship members, for detection of latent islet autoim-
munity (Tuomi et al. 1993). Anti-GAD titers were mea-
sured by radio-ligand assay, as described elsewhere (Pe-
tersen et al. 1994; Bingley et al. 1997). This assay
achieved 100% sensitivity and specificity in the Third
GAD Proficiency Program, in 1997, with an intra-assay
variation of 7%. An anti-GAD titer 110 U (correspond-
ing to ∼8 SD above the mean of 88 normal control
subjects) in duplicate samples was considered positive.
Informed consent for participation was obtained from
all subjects and relatives, after approval had been
granted by the relevant Research Ethics Committees.
Microsatellite Genotyping
Sufficient DNA was available from all ascertained
members in a total of 687 pedigrees at the initiation of
the genotyping analyses. The autosomal genome scan in
these 1,721 individuals used a panel of 418 microsatel-
lite markers based principally on the ABI Prism Link-
age Mapping Set MD-10 (Applied Biosystems), sup-
plemented (where necessary, for reasons of marker per-
formance or heterozygosity) by additional markers op-
timized in-house. All markers were dinucleotide repeats
of the type (CA)n, originally chosen from the Ge´ne´-
thon/CEPH map (Dib et al. 1996). Unlabeled primers
were “PIG-tailed” to facilitate automated allele calling
(Brownstein et al. 1996). After the primary, 418-marker
scan, a further 17 microsatellite markers were typed on
chromosome 1q. Details of all markers used are available
from the Warren 2 Project Information (Wellcome Trust
Centre for Human Genetics, Oxford) web site.
Template DNA (25 ng/reaction) was amplified in sim-
plex 15-ml PCR reactions using Taq Gold polymerase,
according to the instructions supplied with the MD-10
marker set. For each individual, 10–20 PCR products
were pooled into coelectrophoresis panels, on the basis
of pooling ratios designed to normalize signal intensity
across markers. Electrophoresis and signal recording
were performed on ABI377 automated Sequencers (Ap-
plied Biosystems), by a standard protocol, with trace
analysis by GENESCAN and GENOTYPER. Allele call-
ing by the latter program incorporated several compo-
nents: an initial round of fully automated typing with
standardized analysis settings was followed, when re-
quired, by manual inspection and correction. Manually
approved genotypes were then submitted to a pipeline
of rigorous quality-control checks (e.g., absolute and
relative peak intensities and outlier peaks), with a sub-
sequent manual reevaluation (by a second operator) of
selected genotypes. Database-aided quality-control pro-
cedures included confirmation of standard individual
genotypes (CEPH standard 1347-02; Coriell Institute),
plate identity and orientation, and allele size.
Inheritance Checking
Pedigrees containing three or more typed individuals
were examined by PEDCHECK (O’Connell and Weeks
1998), to detect Mendelian inconsistencies. Reported
family relationships in all 687 genotyped pedigrees were
examined by identity-by-descent–based methods imple-
mented in RELATIVE (Go¨ring and Ott 1997) and REL-
PAIR (Boehnke and Cox 1997), with all available geno-
typedmarkers. A familywas excluded if allmethods failed
to produce concordant results. Individuals (or samples)
apparently unrelated to other “family” members were ex-
cluded. Instances of unsuspected half-sib relationships
(present in 27 families) were also excluded, to avoid the
possible influence of biological parents whose adherence
to the ascertainment criteria could not be verified. A “fi-
nal” pedigree data set (573 families) was obtained by
excluding all families that contained one or more mem-
bers positive for anti-GAD antibodies. All analyses re-
ported herein are based on this 573-pedigree data set.
Linkage Analysis
Allele frequencies for the 418 autosomal markers were
estimated on the basis of the entire data set, by RECODE
(Division of Statistical Genetics, Department of Human
Genetics, University of Pittsburgh). Marker order and
intermarker distances were taken from published Ge´ne´-
thon/CEPH maps (Dib et al. 1996) and were converted
into Haldane centimorgans, for multipoint linkage anal-
ysis using ALLEGRO version 1.1b (Gudbjartsson et
al. 2000). All distances quoted herein are relative to the
most p-terminal marker in the Ge´ne´thon/CEPH maps
(Dib et al. 1996), unless otherwise stated. ALLEGRO
implements both the nonparametric linkage (NPL) Z-
score of Kruglyak et al. (1996) and the allele-sharing
LOD score of Kong and Cox (1997), designed to ac-
commodate the conservativeness of the NPL Z-score
when inheritance information is incomplete, as is the
case with missing genotype data. In addition, for the
genome scan and subsequent simulations, ALLEGRO
was preferred over GENEHUNTER (Kruglyak et al.
1996) and GENEHUNTER PLUS (Kong and Cox
1997), for reasons of computational efficiency. The Sall
scoring statistic was used for calculation of the NPL Z-
score (Kruglyak et al. 1996), and the exponential model
was used for the allele-sharing LOD score (Kong and
Cox 1997). Significance levels of LOD scores quoted
herein are nominal, unless otherwise stated.
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Genomewide Exclusion Mapping
As a complement to the search for evidence of linkage,
we conducted exclusion mapping to determine which
genomic regions could be excluded as candidates for
major susceptibility effects, using GENEHUNTER ver-
sion 2.0 (Kruglyak et al. 1996). Five different effect sizes
were considered, under the assumption that the overall
sibling relative risk (lS) for T2D is 3.5 (Ko¨bberling and
Tillil 1982; Rich 1990). Locus-specific relative risks of
3.50, 1.87, 1.52, 1.37, and 1.28 correspond, respec-
tively, to one to five affection-trait loci (ATLs) of equal
effect size acting multiplicatively (Risch 1990). Analyses
were performed under the assumption of no dominance
variance (hence ).l p lS O
Genomewide Empirical-Significance Calculations and
Power Estimates
We determined the genomewide empirical significance
of regions of excess allele sharing that were identified
by our genome scan. A complete genome with marker
characteristics reproducing those observed in the final
pedigree data set (573 families) was simulated under the
null hypothesis of no linkage (by SIMULATE; see the
Lab of Statistical Genetics [Rockefeller University] web
site). Ten thousand replicates (incorporating the exact
pattern of missing genotypes observed in our scan) were
generated and analyzed by ALLEGRO, as above (see the
“Linkage Analysis” subsection). In addition, simulations
were performed to estimate our data set’s power to de-
tect T2D ATLs with different effect sizes. An “average”
chromosome, comprising 20 markers and reproducing
the mean number of alleles, heterozygosity, and marker
spacing of the marker set used, was simulated for the
final pedigree data set, under the assumption of linkage
to a single ATL. As described above (see the “Genome-
wide ExclusionMapping” subsection of the Subjects and
Methods section), five gene-effect sizes were considered,
and an (average) missing-genotype rate of 15% was op-
tionally included. One thousand replicates under each
set of conditions were analyzed by ALLEGRO.
Conditional Analyses
To identify possible interactions between the regions of
excess allele sharing that were identified in the genome
scan, we performed conditional analyses (Cox et al. 1999)
using GENEHUNTER PLUS (Kong and Cox 1997).
Reevaluating the evidence for linkage at one locus after
having accounted for the evidence for linkage at a second,
unlinked but phenotypically correlated locusmay increase
power and indicate the nature of any interaction between
the two (Cox et al. 1999). To control the extent of mul-
tiple testing, we elected only to consider interactions in
which both loci had multipoint LOD scores 1.18 (cor-
responding to [Ott 1999, p. 66]) and in whichP  .01
at least one of the loci had amultipoint LOD score1.50.
Spearman’s correlation coefficient, r, between the family
NPL scores at each pair of loci was calculated by SAS,
release 8.2 (SAS Institute). The evidence for linkage at a
given (“conditioned”) locus was then reevaluated after
each family had been assigned a weight according to the
NPL score at the site of maximal linkage to the other
(“conditioning”) locus. In the case of positive correlations
(indicating possible epistasis), those weights were 1 for
each family with a positive NPL score at the conditioning
locus and 0 for families with 0 or negative NPL scores;
for negative correlations (representing possible hetero-
geneity), weights were 1 when the NPL score at the
conditioning locuswas negative andwere 0when theNPL
score was 0 or positive. When the value of the weighted
LOD score exceeded that of the unweighted LOD score,
the significance of the change was assessed by permuta-
tion: the family-specific weights were permuted, and the
LOD score was recalculated on the basis of the GENE-
HUNTER PLUS probability files.
Ordered-Subset Analysis
Interfamilial differences in associated phenotypes such
as age at onset and body-mass index (BMI) may reflect
clinically and etiologically distinct subsets of T2D. To
explore possible heterogeneity in our data set—and,
thereby, to overcome any associated reduction in power
to detect ATLs—we conducted ordered-subset analyses
(Hauser et al. 1998) of the regions of interest that were
highlighted by our primary genome scan, subsetting ei-
ther on age- and sex-adjusted BMI or on AAD (as a
measure of age at onset). Each family was ranked ac-
cording to the mean value of the associated trait (BMI
or AAD) in diabetic individuals within that family. The
LOD score for linkage to T2D was then recalculated
(under the linear model) at each chromosomal position
in successive data sets formed by adding each family in
rank order. The analysis was conducted in both rank
orders, to ensure detection of subsets at either end of
the phenotypic distribution. The significance of the max-
imized LOD score was determined by 10,000 replicates
of rank permutation and reanalysis, as before.
Results
Characteristics of Analyzed Data Set
The autosomal genome scan was completed on 687
pedigrees. Examination of genotype data with PED-
CHECK, RELATIVE and RELPAIR resulted in exclusion
of 87 pedigrees, on the grounds of demonstrable non-
paternity, half-paternity or inadequate genotype data for
confirmation of presumed family relationships. A further
27 families were excluded on the basis that each contained
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Table 1
Clinical and Family-Structure Characteristics of the






Age at examination (years) 63.7 (8.4) 64.5 (8.4)
AAD (years) 55.2 (8.6) 56.1 (8.6)
BMI (kg/m2)a 27.8 (4.3) 29.8 (5.6)




a Significant difference ( ) between malesP ! .0001
and females.
b Calculated as , where s is the number ofs(s 1)/2
sibs.
c Calculated as , where s is the number of sibss 1
(Suarez and Hodge 1979).
at least one member positive for anti-GAD auto-antibod-
ies and therefore suspected of harboring latent autoim-
mune diabetes (Tuomi et al. 1993). This generated a final
pedigree data set for analysis of 573 pedigrees, corre-
sponding to 743 affected sib pairs. Clinical characteristics
of these families are shown in table 1.
Genotyping Characteristics
Mean marker spacing for the 418 autosomal micro-
satellite markers in the primary genome scan was 9.3
cM (Haldane) with a mean marker heterozygosity of
∼78%. Overall, the success rate for completed genotypes
in the 573 pedigree data set was ∼86%, reflecting the
rigorous quality-control procedures necessary for small
sibships when opportunities for inheritance checking are
limited. The mean entropy-based information content
(measuring the proportion of the total inheritance in-
formation extracted at each chromosomal position,
given the available genotype data [Kruglyak et al. 1996])
of the 418 typed markers was 42% in the two-point
analysis and 51% in the multipoint analysis.
Power Calculations
Power calculations for the 573-pedigree data set under
different values of lS and missing genotype frequency
are presented in table 2. Under the optimistic assumption
of a single ATL for T2D (locus-specific ), therel p 3.50S
was ∼100% power for detection with a LOD score of
3, when an “average Warren 2 marker map” was used,
regardless of the missing genotype rate. Power remained
good (84%) for detection of an ATL of modest effect
( ) with a LOD score of 3, even with 15%l p 1.52S
missing genotypes, and, under similar assumptions, was
close to 100% at a LOD score of 1. Predictably, power
to detect ATLs of smaller effect ( ) with a LODl p 1.28S
score of 3 was poor (27%with 15%missing genotypes),
although such loci should still be detectable at lower
thresholds (∼56% power for a LOD score of 2.0 and
∼86% for a LOD score of 1.0).
Linkage Analysis
Multipoint linkage maps for the autosomes are shown
in figure 1. In all, seven regions showing evidence for
linkage, with multipoint LOD scores 1.18 ( ),P  .01
were detected: 1q24-25 (LOD score 1.50; 209.8 cM),
5q13 (LOD score 1.22; 82.1 cM), 5q32 (LOD score 1.22;
160.8 cM), 7p15.3 (LOD score 1.31; 38.0 cM), 8p21.3-
22 (LOD score 2.55; 42.2 cM), 8q24.21-24.23 (LOD
score 1.41; 162.6 cM), and 10q23.31-23.33 (LOD score
1.99; 125.2 cM) (table 3). The widths, at a LOD score
0.59 ( ), of the three regions showing the bestP  .05
evidence for linkage were estimated: the locus on 1q24-
25 covered an ∼29-cM region between D1S484 and
D1S238; that on 8p21.3-22, an ∼41-cM region between
D8S277 and D8S505; and that on 10q23, an ∼39-cM
region between D10S1730 and D10S1693. There were
three additional regions—on chromosomes 11, 12 and
17—that generated two-point, but not multipoint, LOD
scores1.18 (table 3), and a further six regions—onchro-
mosomes 1, 2, 6, 7, 10, and 11—showed nominal mul-
tipoint evidence for linkage (LOD score0.59) (table 4).
As expected on the basis of the pointwise LOD scores
(Lander and Kruglyak 1995), empirical-significance cal-
culations (10,000 replicates) indicated that none of the
regions reached genomewide significance at ; forP ! .05
example, the 8p21.3-22 locus was associated with a ge-
nomewide empirical-significance level of .098.
Dense Mapping on Chromosome 1q
The linkage results from the primary (∼9 cM) genome
scan highlighted regions on 1q24-25, 8p21-22, and
10q23.3 as being the strongest candidates for dense-map
genotyping. In each case, the inheritance information
extracted by the primary scan was ∼50%. Here, we pre-
sent dense-mapping data for the 1q24-25 region (table
5 and fig. 2). Work on the other regions is in progress
and will be reported elsewhere.
All pedigrees were typed for 17 additional 1qmarkers,
distributed fromD1S498 (174.9 cM) toD1S2682 (313.6
cM) on 1q, with the majority mapping under the broad
1q24-25 peak (fig. 1) and with others in the 1qter region
(around D1S2836, which, on the primary scan, had pro-
vided evidence for linkage, with a two-point LOD score
of 3.63). This resulted in a dense map of 33 markers,
with a mean spacing of 4.4 cM across this region, and
elevated the mean information extraction (entropy) to
∼60% (table 5).
Evidence for linkage in this region increased from a
LOD score of 1.50 in the primary map to a LOD score
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Table 2




No Genotypes Missing 15% of Genotypes Missing
Threshold
LOD Score p 1
Threshold
LOD Score p 2
Threshold
LOD Score p 3
Threshold
LOD Score p 1
Threshold
LOD Score p 2
Threshold
LOD Score p 3
3.50 100 100 100 100 100 100
1.87 100 100 100 100 99.8 99.5
1.52 99.8 98.1 88.8 99.3 95.2 84.3
1.37 98.1 84.9 58.7 96.2 76.1 51.0
1.28 90.4 59.8 30.8 86.3 55.5 26.8
a Derived from simulations of 1,000 replicates of an “average Warren 2 chromosome,” under the assumption that one, two, three, four,
or five ATLs (corresponding to locus-specific lS values of 3.50, 1.87, 1.52, 1.37, or 1.28) contribute to disease.
of 1.98 ( ) in the dense map, betweenPp .0013
D1S2799 and D1S452 (206 cM) on 1q24.2. The width
of this peak of linkage, at a LOD score of 0.59 (Pp
), increased slightly, to ∼32 cM; at a LOD score of.05
1.18 ( ), the width was ∼17 cM. At the samePp .01
time, the excess allele sharing that, in the primary scan,
was observed close to D1S413 (LOD score 0.92 at 236.2
cM; table 4) was reduced considerably (LOD score
0.41), further localizing the locus for this chromosomal
arm, into the region around 206 cM. The region that,
in the primary scan, showed excess allele sharing at 1qter
(around D1S2836) disappeared completely when the ad-
ditional markers were included.
Genomewide Exclusion Mapping
Results from the exclusion mapping of the genome
are shown in table 6. Segregation of an ATL of very
large effect (i.e., ) could be excluded acrossl p 3.50S
the entire autosomal genome, with a LOD score !7.
Exclusion of an ATL with was possible forl p 1.87S
99% of the genome (with LOD score !3), the sole
exception being the region around the peak of allele
sharing, on 8p21-22. At , 92% of the genomel p 1.52S
was excluded (with LOD score !2); only the regions
described above (see the “Linkage Analysis” subsec-
tion)—on 1q24.2, 5q13, 5q32, 7p15.3, 8p21-22,
8q24.2, and 10q23.3 (LOD score 0.99)—and a re-
gion from 44 cM to qter, on chromosome 21 (LOD score
1.19), were not. Modest effect sizes (locus-specific lS
values of 1.37 and 1.28) could be excluded from 78%
and 57% of the genome, respectively, with the same eight
regions being the only ones with positive LOD scores.
Conditional Analyses
As described above, Spearman correlation coefficients,
r, between thefamily NPL scores obtained at the regions
showing maximum evidence for linkage, on 1q24.2,
8p21-22, and 10q23.3, were calculated. Further corre-
lations, between each of these three regions and the
peaks on 5q13, 5q32, 7p15.3, and 8q24.2, were
calculated.
A significant positive correlation was detected be-
tween the 1q24.2 and 10q23.3 loci ( ;rp .099 Pp
), suggesting the presence of epistasis. We detected.018
an increase in the evidence for linkage at 1q24.2 when
dense-map markers were included, after weighting for
the linkage at 10q23.3 under an epistatic model. This
LOD-score increase, from 1.98 to 3.07, was nominally
significant by permutation ( ). In the reciprocalPp .017
analysis, we found a similarly significant increase in the
LOD score at 10q23.3, from 1.99 to 2.78, after weight-
ing for linkage at 1q24.2 ( ). There were noPp .032
significant correlations between either of the two link-
ages on chromosome 8 and any other region of interest.
There was a nominally significant, negative, correla-
tion between 1q24.2 and 5q32 ( ; ),rp .099 Pp .018
suggesting heterogeneity. The evidence for linkage to
1q24.2, when conditioned for linkage to the 5q32 locus,
increased from a LOD score of 1.98 to a LOD score of
3.01 ( ). Again, the reciprocal analysis was alsoPp .023
nominally significant (LOD score increase, at 5q32, to
2.45; ).Pp .010
These exploratory conditional analyses involve 15
tests, independent under the null hypothesis of no in-
teraction. Full adjustment for this aspect of the multiple
testing would render these conditioning results nonsig-
nificant, at .P ! .05
Ordered-Subset Analysis
Ordered-subset analysis was conducted on the chro-
mosome 1q24.2 dense map, with age-at-diagnosis (AAD)
and age- and sex-adjusted BMI being used as the strati-
fying variables. No analysis resulted in a significant in-
crease in the maximized LOD (MOD) score. The baseline
LOD score (under a linear model) of 1.89 increased to
2.57 ( ) for the bottom 84% ( ) of AAD-Pp .20 np 481
ranked families; the reverse ranking gave a MOD score
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Figure 1 Multipoint analyses for the primary 418-marker autosomal genome scan of 573 sib-pair pedigrees. Analyses were performed
on the entire 573-pedigree data set, by ALLEGRO, as described in the text. Allele-sharing LOD scores calculated under the exponential model
are shown.
of 2.43 ( ). When BMI was stratified with a low-Pp .28
to-high ranking, there was no increase in the LOD score;
the reverse ranking yielded a MOD score of 2.65 (Pp
)..29
Discussion
The Warren 2 sib pair repository (see the Warren 2 Pro-
ject Information [Wellcome Trust Centre for HumanGe-
netics, Oxford] web site) represents one of the largest
available collections of families segregating T2D. The
genomewide scan for linkage reported herein is expected,
therefore, to contribute significantly to the global picture
emerging from similar studies in other populations, in-
cluding African American (Ehm et al. 2000), Ashke-
nazim (Permutt et al. 2001), Finnish (Mahtani et al.
1996; Ghosh et al. 2000; Watanabe et al. 2000), French
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Table 3








MULTIPOINT DATAb TWO-POINT DATAb
LOD




D1S196 203.1 75.6 1.28 .0076 .53 (.99) (.016)
Interval 209.8 … 1.50 .0044 .44 … …
D1S218 214.2 79.6 1.46 .0048 .55 1.64 .0030
D1S2836 316.2 81.9 (.41) (.084) (.41) 3.63 .000022
Chromosome 2:
D2S396 262.2 80.1 (.48) (.068) (.53) 1.26 .0079
Chromosome 5:
D5S647 82.1 81.9 1.22 .0088 .54 1.35 .0064
D5S436 160.8 79.0 1.22 .0090 .54 1.46 .0048
Chromosome 6:
D6S262 141.8 88.8 (.70) (.036) (.57) 1.97 .0013
Chromosome 7:
D7S493 38.0 88.1 1.31 .0071 .56 2.26 .00063
Chromosome 8:
D8S520 21.1 79.2 1.22 .0087 .51 (.54) (.056)
D8S549 33.8 51.8 2.11 .00090 .39 (.68) (.039)
Interval 42.2 … 2.55 .00031 .37 … …
D8S258 44.3 71.3 2.49 .00036 .44 2.11 .00091
D8S284 156.1 83.5 1.11 .012 .55 2.50 .00035
Interval 162.6 … 1.41 .0054 .39 … …
D8S272 166.9 75.9 1.28 .0076 .46 (.53) (.058)
Chromosome 10:
D10S1686 119.9 86.0 1.61 .0033 .54 1.09 .012
D10S1765 125.2 86.9 1.99 .0012 .58 1.37 .0060
Interval 127.2 … 1.99 .0012 .52 … …
D10S185 135.0 76.0 1.65 .0030 .53 (.25) (.14)
Chromosome 11:
D11S904 40.1 80.9 (.74) (.032) (.52) 1.65 .0030
Chromosome 12:
D12S351 105.6 75.3 (.49) (.066) (.47) 1.70 .0026
Chromosome 17:
D17S921 40.2 77.4 (.41) (.084) (.46) 3.74 .000017
NOTE.—Results are based on analyses of entire 573-pedigree data set, by ALLEGRO.
a From the most p-terminal marker in the Ge´ne´thon/CEPH map (Dib et al. 1996).
b Entries for which the LOD score is !1.18 are contained within parentheses.
(Vionnet et al. 2000), Mexican American (Hanis et al.
1996; Duggirala et al. 1999; Ehm et al. 2000), Native
American (Hanson et al. 1998), and U.S. individuals of
European descent (Elbein et al. 1999; Ehm et al. 2000).
In particular, synthesis of data from these different ge-
nome scans, most of which, individually, have failed to
generate highly significant linkages in primary analyses,
should improve the prospects for successful identifica-
tion of those regions with the strongest claims for gen-
uine susceptibility effects, thereby targeting positional
cloning efforts toward the most rewarding loci.
Our study has involved a primary (∼9 cM) genome
scan, followed by nonparametric linkage analysis and
exclusion mapping, in a sample of 573 U.K. affected
sibships of European descent. Loci with allele-sharing
LOD scores 1.50 were detected on 1q24.2, 8p21-22,
and 10q23.3; other regions, with LOD scores 1.18
( ), were detected on 5q13, 5q32, 7p15.3, andP  .01
8q24.2. As outlined below (also see table 7), several of
these regions—specifically, 1q24.2, 5q13, 5q32, 8p21-
22, and 10q23.3—coincide with (and, in one case,
clearly replicate) regions of excess allele sharing that
have been identified in other scans. In addition, more-
detailed analyses of the 1q24.2 region of interest have
demonstrated increased evidence for linkage, by use of
dense-map genotyping, and nominally significant evi-
dence for an interaction with other regions of interest,
both of which are consistent with an underlying sus-
ceptibility gene. Finally, by exclusion mapping, we have
been able to exclude, from 92% of the genome, the
presence of a locus with an effect size (i.e., locus-specific
lS) of 1.52, with the remaining 8% representing the
Wiltshire et al.: Type 2 Diabetes in the U.K.: Genome Scan 561
Table 4







MULTIPOINT DATA TWO-POINT DATA
LOD
Score Nominal P Entropy
LOD
Score Nominal P
D1S413 (chromosome 1) 236.2 73.3 .92 .020 .51 .88 .022
D2S391 (chromosome 2) 80.1 76.1 .62 .046 .52 1.15 .010
D6S262 (chromosome 6) 141.8 88.8 .70 .036 .57 1.97 .0013
D7S684 (chromosome 7) 163.9 78.9 .68 .038 .50 .44 .078
D10S196 (chromosome 10) 79.7 73.9 .66 .041 .45 .58 .051
D11S904 (chromosome 11) 40.1 80.9 .74 .032 .52 1.65 .0030
NOTE.—Data are as defined in the footnotes to table 3.
regions of interest on chromosomes 1, 5, 7, 8, and 10,
together with an additional region on 21qter.
Methodological Issues in T2D Genome Scans
Any study aiming to detect complex trait linkages
needs to take explicit account of the reduction in pow-
er that is associated with the anticipated etiological
complexity (as reflected by clinical, genetic, and ethnic
heterogeneity; oligogenicity; and gene-environmental in-
teractions) (Suarez et al. 1994; Risch and Merikangas
1996). The Warren 2 study was designed to mitigate
these factors, in a number of ways. First, the final data
set of 573 pedigrees (generated from 687 typed families
after poor sample amplification, suspected nonpaternity,
and presumed etiological admixture had been taken into
account) represents one of the largest resources studied
for linkage to T2D. As the power studies indicate, this
study size improves the prospects for detection of loci
with modest effects (particularly those with locus-spe-
cific lS values of 1.25–1.50, which remain within the
reach of adequately powered linkage studies [Risch and
Merikangas 1996]). Simulation-based power calcula-
tions demonstrate that our data set had excellent power
to detect either a locus with at a LOD scorel p 1.52S
of 2 (95% power) or a locus with at a LODl p 1.28S
score of 1 (86% power). Second, we have reduced the
risk of etiological heterogeneity by using a wide range
of clinical and laboratory-based measurements, to min-
imize contamination by other known subtypes of dia-
betes; for example, the relatively low prevalence of anti-
GAD antibodies (∼2.5% of all T2D sibs, compared to
17% in unselected T2D groups [Turner et al. 1997])
suggests that the clinical criteria employed were effective
at reducing the admixture of autoimmune diabetes. The
clinical characteristics of the T2D subjects recruited (ta-
ble 1) are, save for an earlier AAD, typical of T2D seen
in clinical practice in the United Kingdom. The advanced
AAD is partly implicit in the ascertainment criteria and
suggests successful enrichment for a relatively early-on-
set, familial T2D phenotype. Third, we have attempted
to reduce the extent of any genetic heterogeneity arising
from ethnic heterogeneity, by recruiting only subjects of
European descent who have at least a three-generation
history of British and/or Irish origin.
The question of how statistical significance should be
attributed to the results arising from a genome scan such
as this remains controversial, but published guidelines
recommend that evidence for linkage should not be de-
clared to be significant unless it has a genomewide sig-
nificance level !.05, equivalent to an allele-sharing LOD
score of 3.63 (Lander and Kruglyak 1995; Nyholt
2000). In our own study, none of the regions showing
evidence for linkage reached this level of significance (the
closest was the 8p21.3-22 locus, with ). ByPp .098
these significance standards, relatively few genome scans
for T2D have detected loci of genomewide significance
in primary (10-cM, nonstratified) analyses (Hanis et al.
1996; Elbein et al. 1999; Ehm et al. 2000).
There are likely to be several factors contributing to
this paucity of strong linkage signals for multifactorial
traits, a phenomenon certainly not restricted to analyses
of T2D. Foremost is the anticipated etiological complexity
of most such traits (see above), which is such that the
effect size attributable to any individual susceptibility lo-
cus will often be modest. It is clear, for example, from
the genome scans conducted for T2D, that, although there
is some evidence for replication between data sets (dis-
cussed below, in the “Comparison of U.K. Findings with
Results of Other Genome Scans for T2D” subsection),
there is, for T2D, no major gene that has a status equiv-
alent to that of HLA in type 1 diabetes (Davies et al.
1994). Other contributory factors include limitations of
current technical and analytical methods. Thus, the typ-
ical 10-cM microsatellite scan fails to capture a consid-
erable proportion of the inheritance information, partic-
ularly in small sibships without parents. Although a
two-stage strategy (with dense mapping in regions of in-
terest that have arisen from the primary scan) may allow
some of this “missing” information to be recovered, this
approach may still miss regions if the evidence for linkage
has, by chance, been underestimated in the primary scan
such that thresholds for dense mapping have not been
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Figure 2 Multipoint analysis of dense-marker map of chro-
mosome 1q: reanalysis of the entire 573-pedigree data set after typing
of an additional 17 markers on chromosome 1q. Allele-sharing LOD
scores are denoted by the unbroken line, and entropy-based infor-
mation content is denoted by the broken line.
Table 5







MULTIPOINT DATA TWO-POINT DATA
LOD
Score Nominal P Entropy
LOD
Score Nominal P
D1S2681 197.9 78.7 1.19 .0095 .64 (.09) (.26)
D1S196 201.6 75.6 1.91 .0015 .65 (.99) (.016)
D1S2799 203.8 85.2 1.94 .0014 .67 2.36 .0005
Interval 206.0 … 1.98 .0013 .60 … …
D1S452 209.4 73.3 1.80 .0020 .64 1.48 .0046
D1S218 212.1 79.5 1.59 .0034 .65 1.74 .0023
NOTE.—Data are as defined in the footnotes to table 3.
attained. In addition, undiscovered residual genotyping
errors (extremely difficult to eliminate entirely in typical
sib-pair data sets when opportunities for Mendelian
checking are limited) (Ewen et al. 2000) may have a dis-
proportionate effect on the power to detect linkage, es-
pecially linkage to loci of modest effect (Douglas et al.
2000; Abecasis et al. 2001). Finally, since complex-trait
susceptibility reflects the interactions of multiple genes,
analytical methods capable of modeling suchmechanisms
may yield improved power over current “locus-by-locus”
approaches (Goddard et al. 2001).
It is important to emphasize, with reference to assess-
ment of the statistical significance of our findings, that
the primary analyses reported herein (and the related em-
pirical significance calculations) include the entire data set
of 573 pedigrees, without any additional stratification or
analytical manipulation. In a sib-pair data set such as
ours, in which the information extraction from a primary
9-cM scan is relatively modest, additional genotyping
planned in these and other families available to us may
increase the evidence for linkage for some of these regions.
However, given the considerable investment in obtaining
the genotype data, as well as the expectation that the
power to detect ATLs may be enhanced by further data
exploration (albeit at the cost of an increase in type 1
error rates [Lernmark and Ott 1998; Leal and Ott 2000;
Cardon and Bell 2001]), we have also initiated stratifi-
cation and conditional analyses of our data.
Stratification is designed to address latent etiological
heterogeneity within the data set (Leal and Ott 2000).
Ordered-subset analysis (Hauser et al. 1998) obviates
possible arbitrariness implicit in a priori stratification
and has previously been applied both to T2D, as part
of the FUSION study (Ghosh et al. 1999, 2000), and to
alcoholism, in the COGA study (Watanabe et al. 1999a).
Conditional analysis, which, in essence, is pedigree strat-
ification by mean allele sharing, is designed to derive
additional power by taking explicit account of the oli-
gogenic basis of complex-trait phenotypes (Cox et al.
1999). This approach has contributed to the identifi-
cation of CAPN10 as a susceptibility gene for T2D in
Mexican Americans (Horikawa et al. 2000), by dem-
onstrating significant epistatic interaction between two
regions of linkage that were identified in the original
genome scan (Hanis et al. 1996; Cox et al. 1999). Some
of the most persuasive linkage evidence observed in other
recent T2D genome scans has arisen through such ex-
ploratory analyses (Mahtani et al. 1996; Hanson et al.
1998; Vionnet et al. 2000).
Comparison of U.K. Findings with Results of Other
Genome Scans for T2D
In the absence of highly significant evidence for linkage
in most populations studied, the importance of comparing
the data from multiple genome scans is well established
(Lander and Kruglyak 1995; Hanis et al. 1996; Lernmark
and Ott 1998). Replications of linkage results from ad-
ditional populations, whether as extension/follow-up
studies in the same population or as independent genome
scans in different populations, provide vital confirmation
of the original findings, and guidelines regarding the level
of significance necessary in order to declare replication
have been suggested (Lander and Kruglyak 1995). The
importance of linkage peak location, in addition to peak
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Table 6
Exclusion-Mapping Data for Warren 2 Genome Scan
CHROMOSOME
PROPORTION OF CHROMOSOME
EXCLUDED AT LOD SCORE !2.0
WHEN LOCUS-SPECIFIC lS p
(%)
1.28 1.37 1.52 1.87 3.50
1:
Primary map 68 74 86 100 100
Dense map 76 85 92 100 100
2 63 86 100 100 100
3 70 83 100 100 100
4 51 93 100 100 100
5 35 58 77 100 100
6 60 80 100 100 100
7 34 49 73 100 100
8 14 35 56 84 100
9 85 100 100 100 100
10 20 31 61 100 100
11 67 88 100 100 100
12 73 87 100 100 100
13 86 94 100 100 100
14 78 100 100 100 100
15 64 100 100 100 100
16 16 88 100 100 100
17 63 78 100 100 100
18 87 100 100 100 100
19 81 97 100 100 100
20 62 100 100 100 100
21 56 63 82 100 100
22 9 75 100 100 100
Entire genome 57 78 92 99 100
height, in the context of replication has received recent
attention (Hauser and Boehnke 1997; Roberts et al.
1999). Simulation studies have demonstrated that very
considerable variation can exist in the location estimate
(i.e., the position of the maximum LOD score relative to
the true location of the susceptibility gene). Not surpris-
ingly, larger sample sizes, larger gene effects, and denser
maps all yield better localization (Hauser and Boehnke
1997; Roberts et al. 1999).
Table 7 summarizes, in the context of our own find-
ings, the results of the major T2D genome scans per-
formed thus far. The clearest evidence for correspon-
dence between multiple data sets is obtained for the 1q
region. Our linkage results here concord strongly with
results from three published scans (Hanson et al. 1998;
Elbein et al. 1999; Vionnet et al. 2000) and with further
data from analysis of Amish pedigrees (St. Jean et al.
2000). Elbein et al. (1999) identified a T2D locus be-
tween CRP and APOA2 on 1q21-23, in a population of
42 multigenerational pedigrees resident in Utah that are
of northern-European ancestry, with an allele-sharing
(Kong and Cox 1997) LOD score of 2.260, and a par-
ametric LOD score of 4.295, under a recessive model
with an age-dependent penetrance function. In their
study of Pima Indians, Hanson et al. (1998) observed
evidence for linkage of T2D to both D1S2127 on
1q25.3, with a LOD score of 4.1, in a subset of 55 sib
pairs (with age at onset !25 years) taken from their study
population of 264 nuclear families, and to D1S1677 on
1q23.3, with a LOD score of 2.5 in a Haseman-Elston
analysis comparing sib pairs concordant for T2D versus
those discordant for the disease. Most recently, Vionnet
et al. (2000) also found evidence for T2D linkage, be-
tween D1S498 and D1S484 on 1q21-24, with a maxi-
mum-likelihood binomial (MLB)-LOD score of 2.47, in
a subset of 57 pedigrees with T2D and BMI !27 kg/
m2, that were selected, by stratification, from their
study population of 148 French families of European
descent with either T2D or glucose intolerance. Fine
mapping of this region with an additional 16 markers
increased their evidence for linkage at D1S484/APOA2,
with an MLB-LOD score of 2.99.
Further support for the importance of this region
comes from analyses in the Goto-Kakizaki (GK) rat, a
nonobese animal model of T2D. These analyses have
identified a locus on rat chromosome 2 (Galli et al. 1996;
Gauguier et al. 1996), in a region syntenic with human
1q21 (Watanabe et al. 1999b); in one GK-rat genome
scan (Galli et al. 1996) the locus, Niddm2, was impli-
cated in glucose tolerance (LOD score 4.82), whereas in
the second (Gauguier et al. 1996) scan it wasmost clearly
linked to fasting insulin levels.
In our data set of U.K. families, the strongest evi-
dence for linkage in this region was obtained between
D1S2799 and D1S452, in our dense map, with a LOD
score of 1.98. This locus, together with those detected
in the Utah, Pima and French studies, fall within an ∼30-
cM interval on 1q. This variation in the localization of
the 1q locus is modest compared with both the width
of the linkage peaks in these studies (∼32 cM, at P !
, in the U.K. study) and the imprecision of location.05
estimates as indicated by theoretical analyses (Hauser
and Boehnke 1997; Roberts et al. 1999). These obser-
vations are therefore entirely consistent with detection
of a common susceptibility locus in the different studies.
The statistical interactions between this locus and other
regions of interest in the U.K. genome scan provide ad-
ditional support.
In accordance with published guidelines (Lander and
Kruglyak 1995), our findings from the dense-map ge-
notyping of chromosome 1q in the U.K. families, in com-
mon with the findings from the French study (Vionnet
et al. 2000), constitute replication of the linkage on 1q,
which previously had been observed in analyses of Utah
families (Elbein et al. 1999) and in Pima Indians (Hanson
et al. 1998). The observations from the GK-rat scans
add further compelling evidence that the 1q locus con-
tains a T2D-susceptibility gene of global importance.
Examination of available human genome sequence (In-
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2001) for the region (from clones with GenBank acces-
sion numbers AP002532–AL022310; ∼20 Mb), by pub-
licly available (ENSEMBL [see the Project Ensembl web
site]) and in-house (GANESH [see the Genome Integrat-
ed Force in Type 2 Diabetes web site]) genome-annota-
tion tools, identifies 133 known genes, including several
strong candidates, such as the gamma subunit of the re-
tinoid X receptor (RXRG [MIM 180247]), lamin A
(LMNA [MIM 150330]) and the potassium inwardly rec-
tifying channel subfamily Jmember 9 (KCNJ9 [LocusLink
accession number 3765]). The region also contains a fur-
ther 145 putative transcripts with homology to known
genes, in addition to as many as 393 further “potential
expressed” sequences based on in silico prediction,mouse
genome comparison, or expressed-sequence-tag similarity
alone. We are engaged in further fine-scale mapping and
positional candidate analysis of this region.
Several other regions highlighted in the U.K. scan cor-
respond to regions identified in other T2D studies. Evi-
dence for linkage on chromosome 5q has been demon-
strated previously in populations of Europeandescent that
are from the United States (Ehm et al. 2000) and France
(Vionnet et al. 2000). In their study population of 77
nuclear families containing 198 sib pairs affected with
either T2D or impaired glucose homeostasis, Ehm et al.
(2000) found evidence for linkage to D5S1404 on 5q13,
with a LOD score of 3.26; however, they were unable to
reproduce this result in a second sample of U.S. individ-
uals of European descent. D5S1404 falls ∼4 cM telomeric
to D5S647, the 5q13 marker that, in our study, shows
maximum evidence for linkage. The genome scan of 148
French families (Vionnet et al. 2000) detected maximum
evidence for linkage, in their entire data set, on 5q31-33,
between D5S410 and D5S436 (MLB-LOD score 1.52),
in the same location as in the U.K. study. In addition, a
genome scan of 158 French families, for genes predis-
posing to obesity (Hager et al. 1998), detected evidence
for linkage between BMI and markers D5S647 on 5q13
(maximum LOD score 1.57), and D5S436 on 5q32 (max-
imum LOD score 1.19), the same markers that in our
study showed evidence for linkage. Taken together, these
results suggest the possibility of loci on chromosome 5q
that are responsible for a broader metabolic dysfunction,
underlying both T2D and obesity.
The study by Elbein et al. (1999), of Utah families of
European descent, found modest evidence for linkage to
two regions on 8p. The first region, on 8p12 (D8S87–
D8S532; LOD score 1.365), falls ∼25 cM(K) (K p Ko-
sambi distances, according to theMarshfield map (see the
web site of the Center for Medical Genetics, Marshfield
Medical Research Foundation) from the locus that we
found on 8p21-22; however, the second region, on 8p21.3
(D8S136; LOD score 1.348), falls within 5 cM(K). Given
the importance of disordered lipidmetabolism as a feature
of T2D and the metabolic syndrome, the gene for lipo-
protein lipase (LPL [MIM 238600]) represents one plau-
sible regional candidate. This region on 8p21-22 is cur-
rently being subjected to fine-scale mapping using the
family resources described in the present study.
Three previous T2D studies in humans have obtained
evidence for linkage to 10q. In their study population
of 27 extended Mexican American families, Duggirala
et al. (1999) observed evidence for linkage between a
locus close to D10S587 and both T2D (LOD score 2.88)
and age at onset of T2D (LOD score 3.75). This region
on 10q26.12 is ∼45 cM telomeric to the region on
10q23.3, where the present study has found maximum
evidence for linkage (LOD score 1.99). The French ge-
nome scan (Vionnet et al. 2000) has reported evidence
for linkage to D10S1655 (MLB-LOD score 1.59) and
D10S212 (MLB-LOD score 1.44) on 10q26.3 (∼50
cM(K) [Center for Medical Genetics, Marshfield Med-
ical Research Foundation] telomeric to the peak in our
study), in subsets of 147 and 65 families, respectively.
The possibility that these observations regarding 10q26
and 10q23 constitute evidence for the same T2D-sus-
ceptibility locus cannot be discounted entirely, given the
substantial variation possible in location estimates (Hau-
ser and Boehnke 1997; Roberts et al. 1999), but this
seems unlikely. The FUSION study (Ghosh et al. 2000)
detected only nominal evidence for linkage to the 10q
region in its primary analysis of a complete data set of
478 Finnish pedigrees (containing 719 affected sib
pairs); however, an ordered-subset analysis, with pedi-
grees ranked on the basis of the mean value of the fasting
insulin:fasting glucose ratio (IR1), obtained more-sub-
stantial evidence for linkage, between D10S185 and
D10S1267 on 10q23.33-24.32 (maximum LOD score
3.12), in the 40 families with the lowest IR1 value. This
region coincides with the locus on 10q23.3, where the
present study has found evidence for linkage.
Studies in the GK rat provide circumstantial support
for the locus on 10q23.3, in that both genome scans with
this model (Galli et al. 1996; Gauguier et al. 1996) map
a locus for poststimulation glycemia (either Niddm1 or
Nidd/gk1) to a rat chromosome 1 region syntenic with
human 10q23-26 (Galli et al. 1999; Watanabe et al.
1999b; Kaisaki et al. 2000). Subsequent dissection of the
Niddm1 region in congenic strains has identified two con-
tributing loci, Niddm1b and Niddm1i, each containing
at least one gene (Galli et al. 1999). Further analyses have
mapped Niddm1b to a 1-cM region containing the gene
for insulin-degrading enzyme (IDE [MIM 146680])
(Fakhrai-Rad et al. 2000). Two amino acid substitutions
in IDE, specific to the GK-ratNiddm1b allele, were found
in the congenic strains and, when present together, con-
ferred postprandial hyperglycemia, reduced insulin deg-
radation in isolated muscle cells, and other diabetes-re-
lated phenotypes (Fakhrai-Rad et al. 2000). In previous
studies, human IDE had been mapped to 10q23-25
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(Affholter et al. 1990; Espinosa et al. 1991) and, recently,
has been more precisely localized, to 10q23.33, in the
draft human genome sequence (International Human Ge-
nome Sequencing Consortium 2001). The evidence for
linkage, in the neighborhood of the human IDE locus, to
T2D and related traits in Mexican American and French
populations has been noted elsewhere (Galli et al. 1999;
Fakhrai-Rad et al. 2000), although (see above) IDE lies
∼45 cM centromeric. IDE falls within the interval be-
tween D10S1765 and D10S185, which lies at the peak
of linkage in our study. The observations from the FU-
SION ordered subset, together with the recent studies in
Niddm1b-congenic rat strains and the synteny between
rat and human genomes in this region, substantially
strengthen the candidacy of IDE for the 10q23.3 locus.
We are currently pursuing fine-scale marker typing and
candidate-gene studies, to further characterize this locus
on 10q23.3.
To the best of our knowledge, the remaining two
regions of interest in our genome scan (i.e., 7p15.3 and
8q24.2) are novel and have not been highlighted by pre-
vious studies, although two groups (Ehm et al. 2000;
Vionnet et al. 2000) observed modest evidence for link-
age on 8p22, 50 cM from the peak of linkage in the
present study. Further studies will be necessary in order
to determine whether these are false-positive results or
represent genuine evidence for linkage to loci of small
effect.
Finally, we note that, in four chromosomal locations
strongly implicated in other genome scans, the present
study’s U.K. genome scan has failed to detect even nom-
inal evidence for linkage to T2D.We detected no positive
allele sharing in that region of chromosome 2qter (par-
ticularly D2S125) which shows significant evidence for
linkage in Mexican Americans (Hanis et al. 1996; Hor-
ikawa et al. 2000) and were able to exclude this region
for . We did detect positive, but nonsignificant,l  1.28S
allele sharing ∼30 cM centromeric to D2S125 (LOD
score 0.48; ), which could be excluded forPp .068
only. We found no positive allele sharing atl  1.52S
the 12q locus detected in Finns (Mahtani et al. 1996)
and U.S. individuals of European descent (Bowden et al.
1997) and were able to exclude this region for l S
. A second locus on 12q, observed in U.S. individ-1.28
uals of European descent (Bektas et al. 1999; Ehm et al.
2000) and ∼50 cM centromeric to that in the Finnish
study, showed positive, but nonsignificant, allele sharing
in our study (LOD score 0.49; ) and could bePp .066
excluded for . The locus detected on 20q inl  1.52S
U.S. individuals of European descent (Bowden et al.
1997; Ji et al. 1997) and in Finns (Ghosh et al. 1999,
2000) showed no evidence of positive allele sharing our
study and could be excluded for . These datal  1.28S
for chromosomes 12q and 20q extend to the full cohort
the findings previously reported for these regions in a
subset of the same pedigrees (Frayling et al. 2000).
Concluding Remarks
The results of this genome scan of 573 pedigrees pro-
vide further confirmation that no single locus plays a
major role in T2D susceptibility. Given the modest de-
gree of familial aggregation ( ) associated withl ∼ 3.5S
T2D, linkage-based gene-discovery studies (particularly
if limited in size) are often operating close to the limits
of detection for the locus-specific effect sizes anticipated.
Nevertheless, two recent developments in particular pro-
vide substantial encouragement. The first of these two
developments is the availability of published genome-
scan data from multiple ethnic groups and the increasing
trend for submission of genotypes to central data re-
positories, allowing combined analyses of very large data
sets (examples include the European Genome Integrated
Force in Type 2 Diabetes [GIFT] consortium and the
International Type 2 Diabetes Linkage Analysis Con-
sortium; also see Boehnke and The International Type
2 Diabetes Linkage Analysis Consortium 1998). The sec-
ond development is the availability of novel analytical
approaches, such as conditional analysis and ordered-
subset analysis, which aim to improve, through detailed
exploration of available data sets, the power to obtain
evidence of linkage. Confirmation of hypotheses arising
from such exploratory approaches in additional data sets
(facilitated by access to large combined data repositories)
should make it possible to address concerns about the
type 1–error inflation associated with the unrestricted
proliferation of exploratory analyses.
The U.K. genome-scan data presented here contribute
to the evolution of our understanding of T2D etiology,
by providing replication (according to published guide-
lines) of a linkage previously reported for chromosome
1q. In addition, regions of interest identified, in other
European data sets, on chromosomes 5q, 8p, and 10q
receive strong support from our data. We expect these
data to accelerate efforts to positionally clone the sus-
ceptibility genes mapping to these regions and, thereby,
to advance the understanding and treatment of this ma-
jor worldwide health concern.
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